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Abstract
Paragangliomas (PGLs) are rare neural tumors that can be benign or malignant and often associated with familial syndromes. We present a case 
of a 23-year-old male with a large retroperitoneal PGL found incidentally during the workup of elevated liver enzymes. After surgical excision, 
the patient was found to have an autosomal dominant mutation in the succinate dehydrogenase B (SDHB) gene, which when compared to 
sporadic PGLs or other familial syndromes is associated with a higher risk of tumor recurrence, occult metastasis, and development of other 
cancers. The patient’s first-degree relatives were recommended to undergo screening for the genetic mutation.
Keywords: incidentaloma; paraganglioma; pheochromocytoma; retroperitoneal tumor; SDHB gene mutation
Received: 14 April 2020; Accepted after revision: 26 October 2020; Published: 25 January 2021.
Author for correspondence: Wen Min Chen, Department of Urology, 42 W Warren Ave, Detroit, MI 48202, United States. Email: wenmin@
wayne.edu
How to cite: Chen WM et al. Large retroperitoneal paraganglioma associated with germline mutation of the succinate dehydrogenase gene. 
J Kidney Cancer VHL. 2021;8(1): 12–18.
DOI: https://doi.org/10.15586/jkcvhl.v8i1.129
Copyright: Chen W M et al.




Paragangliomas (PGLs) are highly vascular, neural crest- 
derived tumors that originate in the ganglia of the sympa- 
thetic and parasympathetic nervous systems or from adrenal 
chromaffin cells at extra-adrenal sites. When found in the 
adrenal gland, PGLs are better known as pheochromocy-
tomas (PCC). These rare neural tumors can have benign 
or malignant potential, and while the majority occur spo-
radically, approximately 25% are associated with familial  
syndromes (1). Hereditary PGL-PCC syndromes are associ-
ated with the inheritance of mutations in the subunits A, B, 
C, D of the gene encoding succinate dehydrogenase (SDH). 
When familial inheritance is identified, prudent surveillance 
is needed, as increased potential arises for the development 
of PGLs, PCCs, and other tumors such as GIST, renal, thy-
roid, and breast cancer. We describe a case of a large retro-
peritoneal PGL found incidentally during the workup of 
elevated liver enzymes, in which the patient was ultimately 
found to have a likely pathogenic mutation in the succinate 
dehydrogenase B (SDHB) gene.
Ethics Approval
Relevant approvals and exemptions were granted by insti-
tutional ethics review boards. Informed consent obtained in 
writing was given by the patient. 
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The CT-guided needle biopsy identified the mass as a PGL, 
and the patient was referred for consideration of surgery. The 
patient denied headaches, excessive diaphoresis, palpitations, 
or paroxysmal hypertension. Laboratory studies including 
plasma catecholamines, plasma metanephrines, 24-hour 
urine catecholamines and metanephrines, brain natriuretic 
peptide, and cortisol were normal. Although the blood work 
suggested no evidence of adrenergic hypersecretion, doxaz-
osin was prescribed out of caution in preparation for surgery.
Two months after diagnosis, the patient underwent com-
plete excision of the mass. To minimize the risk of ureteral 
injury, the operation began with cystoscopic placement of a 
localizing right ureteral catheter. Intraoperatively, the mass 
was firmly adherent to the inferior vena cava (IVC) resulting 
Case Report
A 23-year-old male in good health was found to have ele-
vated liver enzymes during a routine physical examina-
tion. An ultrasound ordered to evaluate the liver noted the 
presence of a large, vascular mid-abdominal mass. Further 
imaging by CT confirmed a large, right retroperitoneal mass 
measuring 16 x 10 x 13.7 cm encasing the vena cava infe-
rior extending from the renal veins to the bifurcation of the 
common iliac veins (Figure 1). Additionally, the CT noted 
leftward displacement of the abdominal aorta, and ante-
rior displacement of the vena cava and lateral displacement 
of the right ureter. There was no evidence of metastasis to 
lymph nodes, bone, liver, or lung. 
Figure 1: CT abdomen/pelvis with IV contrast – demonstrating 16 x 10 x 13.7 cm retroperitoneal mass encasing and displacing 
the IVC anteriorly, the ureter medially, and the aorta laterally. The mass extends from the renal vessels to the common iliac 
vessels.
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syndrome 4. He was informed that his syndrome confers a 
high risk of occult metastasis, the risk for developing reoc-
currence of his PGL, as well as the development of other 
tumors: renal cell carcinoma, GIST, thyroid, and breast can-
cer. A 68Ga-labeled [DOTATATE] PET scan was ordered 
to better characterize the patient’s current disease burden. 
Although uptake was seen in several bone areas (Figure 4), 
systemic treatment will be withheld as the tempo of dis-
ease progression may be slow. The patient’s immediate fam-
ily members were recommended to undergo genetic testing 
given the 50% risk to each first-degree relative of carrying the 
familial SDHB mutation. 
in multiple vena cavotomies. The vena cava was repaired and 
preserved; otherwise, no viscera were injured. He was dis-
charged home 6 days after an uncomplicated postoperative 
course. The pathology report confirmed the diagnosis of 
PGL and identified the mass to be synaptophysin and chro-
mogranin positive (Figures 2 and 3). 
Postoperative MRI displayed interval resection of the ret-
roperitoneal mass and no signs of metastatic disease. Due to 
the patient’s young age, the patient was referred for genetic 
counseling. Genetic testing revealed a likely pathogenic ger-
mline mutation (c.289A>T) in the SDHB gene. Thus, the 
patient was diagnosed with autosomal dominant PGL-PCC 
Figure 2: Histologic sections show: (a) The zellballen pattern (small, nested, organoid), which is characteristic of PG, features 
rounded nests of tumor cells within a vascularized fibrous stroma. (b) The vessels are often compressed and sinusoidal, but 
larger ectatic or “staghorn” vessels can also be seen. (c) Centralized areas with loose, edematous stroma can be seen within, 
which results in the micronodular appearance of tumor cells. Bands of collagen of variable width are also seen. (d) Tumor 
cells contain finely granular, eosinophilic cytoplasm and regular, centralized nuclei; some might show nucleoli. (e) Intranuclear 
pseudoinclusions are numerous. Nuclear enlargement and pleomorphism are also seen. These findings have no prognostic signif-
icance in isolation. (f) Clear cell change due to cytoplasmic vacuolization, sometimes quite prominent with bubbly appearance, 
suggests a lipoblastic differentiation. (g) Tumor cells show an accumulation of dark intracytoplasmic pigment. These pigments 
are often neuromelanin; however, lipofuscin and hemosiderin can also be seen (22).
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Discussion
Paragangliomas and their adrenal counterpart, pheochro-
mocytomas, are rare tumors with an incidence of 0.6 cases 
per 100,000 persons-year. While most occur sporadically, a 
significant proportion can be associated with germline muta-
tions and familial syndromes. Classically, they are associated 
with a constellation of symptoms attributed to the hyperse-
cretion of metanephrines: headaches, paroxysmal hyperten-
sion, palpitations, flushing, and profuse sweating. When a 
PGL/PCC is suspected, the initial evaluation is completed 
with plasma metanephrines and CT abdomen/pelvis with IV 
contrast. However, in our case, the PGL was found inciden-
tally after an abdominal ultrasound was performed for ele-
vated liver enzymes (11). The patient’s tumor was found to 
be intra-abdominal and extra-adrenal which is characteristic 
of the more aggressive forms of sympatho-adrenal neuroen-
docrine tumors. PGLs can be benign tumors or malignant, 
which is defined by metastasis identified at the time of diag-
nosis since there are no pathologic or cellular markers of 
malignancy. 
Additional imaging with positron emission tomography 
(PET)/CT is warranted when the tumor size is greater than 
>10 cm. Functional imaging with PET-CT using 68Ga- labeled 
1,4,7,10 tetraazacyclododecane—1,4,7,10-tretraacetic acid 
octeotride [DOTATATE] is more effective than traditional 
Fluorodeoxyglucose (FDG)-PET in localizing PGLs/PCCs 
as well as any metastatic deposits. In our case, this was per-
formed after the tumor was removed and showed multiple 
sub-centimeter boney deposits concerning metastasis (2). 
Surgical resection is the mainstay of the treatment of 
PGLs/PCCs. In most cases, preoperative beta and alpha-ad-
renergic blockade is warranted. Our patient did not have 
elevated metanephrines but was treated preoperatively with 
doxazosin out of caution. As mentioned before, most PGLs 
are diagnosed based on clinical manifestations of cate-
cholamine hypersecretion; however, patients with asymp-
tomatic retroperitoneal PGLs are most commonly found 
incidentally on imaging or during family screening for 
hereditary syndromes (3). The asymptomatic nature of our 
patient’s mass enabled it to grow to a considerable size in the 
retroperitoneum. 
It is estimated that up to 40% of patients who present with 
PGLs/PCCs carry an identifiable germline mutation. To date, 
at least 18 gene mutations have been identified that can result 
in PGLs/PCCs, of which five familial PGL syndromes have 
been described and named PGL-1 through PGL-5 (4,  5). 
The genetic defects underlying these syndromes affect the 
subunits of the mitochondrial enzyme succinate dehydro-
genase: PGL-1 is associated with mutations in the SDHD 
gene encoding for the D subunit of succinate dehydrogenase, 
PGL-2 is associated with SDHAF2, PGL3 to SDHC, PGL4 
to SDHB, and PGL5 to SDHA (5–9). Typically, retroperito-
neal PGLs are associated with SDHD, SDHB, and SDHA 
mutations. Carriers of mutations in SDHB have variable 
penetrance (40% by age 40), often present with extra-adrenal 
retroperitoneal tumors, and have a high risk for metastasis 
at the time of presentation. The average age at diagnosis of 
index cases is 34, although there have been reports of index 
Figure 3: Tumor cells show diffuse expression of neuroendocrine markers, including synaptophysin (a) and chromogranin (b). 
S100 protein (c) highlights sustentacular cells or modified Schwann cells. These sustentacular cells surround nests of tumor cells 
in PG, and is characterized by thin, delicate cytoplasmic processes and nuclei.
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protocols for asymptomatic SDH mutation carriers found 
that abdominal MRI every 18 months with MRI of the neck, 
thorax and pelvis every 3 years is unlikely to miss a signifi-
cant lesion (13, 14). 
In the event metastatic disease is found, radiotherapy, 
chemotherapy, and immunotherapy are viable treatment 
options. Radiotherapy, in the form of peptide receptor radio-
nuclide therapy (PRRT), uses drugs or substances tagged to 
radionuclides that bind to specific peptide receptors that are 
overexpressed on cancers cells causing targeted cell death 
with minimal side-effects (15). High-specific-activity I-131-
MIBG (HSA-I-131-MIBG) is a norepinephrine analog that 
is taken up by the noradrenaline transporter expressed in 
neuroendocrine cells and is the standard of care for patients 
with MIBG-avid tumors (16). Currently, HSA-I-131-MIBG 
is the only FDA approved therapy in the US for metastatic 
PCC and PGLs, and is the focus of promising future research 
regarding efficacy enhancement as only around a third of 
patients can see a clinical benefit (16). Astatine-211-labeled 
MIBG (At-211) is another type of PRRT that uses alpha par-
ticles as opposed to the standard beta particles used in radio-
nuclide therapy allowing for a higher linear energy transfer 
and cytotoxicity (15). At-211 has yet to undergo clinical 
utility studies but has significant therapeutic potential as a 
novel PRRT agent. Additionally, chemotherapy using cyclo-
phosphamide, vincristine, and dacarbazine (CVD) remains 
an option for metastatic neuroendocrine tumors. A meta-
analysis performed by Niemeijer et al. (17) found that CVD 
chemotherapy was able to produce partial response concern-
ing tumor volume in 37% of patients and partial response 
concerning catecholamine excess in 40% of patients. Fur-
thermore, the complete response for tumor volume and cat-
echolamine excess was found to be 4 and 14%, respectively. 
The alkylating agent temozolomide has also shown promise 
in treating metastatic neuroendocrine tumors, with one study 
reporting a 70% reduction in tumor size in a SDHB-muta-
tion-positive patient (18). Side effects of these chemotherapy 
regimens including myelosuppression, peripheral neurop-
athy, and gastrointestinal toxicity can lead to high rates of 
treatment discontinuation. This can be exacerbated if  the 
cancer is nonresponsive to CVD chemotherapy initially, lead-
ing to a significantly low number of cycles tolerated by these 
patients. Overall, the systemic side effects in conjunction 
with the inconsistent response rate among patients prevent 
chemotherapy from being used as a first-line agent. Usually, 
it is reserved for patients with a high tumor burden or a large 
number of bone metastases (19). Sunitinib, a receptor tyro-
sine kinase inhibitor, which targets receptors for a vascular 
endothelial growth factor (VEGF), has also been studied as 
a systemic treatment option for metastatic disease. Favier 
et al. (19) found that increased VEGF expression reflected an 
overrepresentation of SDHB-related tumors. While not yet 
approved for PCC/PGL, a preliminary study of sunitinib has 
cases before the age of 10 (1). Therefore, screening may begin 
as early as 5–10 years of age in patients positive for SDHB 
mutation. Screening should entail a careful history and phys-
ical examination, annual measurement of blood pressure and 
urinary catecholamines/metanephrines, and biennial CT or 
MRI imaging (neck, thorax, abdomen, and pelvis) (1). 
The mechanism of tumorigenesis in PGLs/PCCs is not 
completely understood but may be related to the hypoxia- 
inducible factor (HIF)/angiogenesis pathway. Succinate dehy-
drogenase is involved in both the electron transport chain 
(ETC) and the Krebs cycle. The SDH complex converts suc-
cinate to fumarate in the Krebs cycle, producing FADH2, 
which is subsequently oxidized to flavin adenine dinucleotide 
(FAD) by SDH in the ETC. The protein has four subunits, 
each having a distinct role in enzymatic function. Our patient 
has a mutation in the B subunit which is a hydrophilic protein 
that makes up a major portion of the catalytic site (4). When a 
mutation in the B subunit is present, the conversion of succi-
nate to fumarate is disrupted leading to a buildup of succinate 
in the cell. The excess succinate diffuses from the mitochon-
dria to the cytoplasm and inhibits prolyl hydroxylase, which 
stabilizes the HIF (4). HIF is a transcription factor that mod-
ulates the expression of genes responsible for pro-angiogenic 
factors, cell proliferation, glycolytic metabolism, and proteins 
involved in metastasis and tumor cell dedifferentiation (10). 
The management of patients found to have SDHB gene 
mutations must be tailored to the individual since presen-
tation can be varied: age of presentation, location of the 
primary tumor, metastases at diagnosis, benign PGLs, and 
identification of concomitant non-PGL tumors. Under the 
direction of a multi-disciplinary team, both medical and sur-
gical options should be utilized (11). After resection, close 
surveillance is particularly warranted in patients with PGL4. 
When compared to other PGL syndromes, PGL4 has a 
higher rate of metastasis at diagnosis, risk of recurrence, and 
risk of developing other primary tumors due to SDHB’s role 
as a tumor suppressor (11, 12). Associations have been found 
between PGL4 and the development of renal cell carcinoma 
(14%), gastrointestinal tumors (GIST) (2%), and head and 
neck PGLs (20–30%) (5). 
After resection of a PGL/PCC long-term surveillance 
should be conducted based on the SDH subunit-specific 
mutation identified. For carriers of SDH(B) mutation, there 
is much debate regarding the frequency and modality of 
surveillance, since there is variable penetrance and limited 
long-term follow-up data in the literature. Finally, missing a 
significant lesion could result in metastatic disease with poor 
prognosis. It is recommended that at the time of diagnosis 
a metastatic workup with functional imaging be conducted 
(13, 14). If  no metastatic disease is found, lifelong surveil-
lance is recommended, preferably with MRI to avoid cumu-
lative radiation exposure. The frequency of imaging is still 
highly debated, however, a systematic review of surveillance 
Paraganglioma associated with a germline mutation 
 Journal of Kidney Cancer and VHL 2021;8(1): 12–18 17
shown significant therapeutic benefits in patients including 
a reduction in tumor size, decreased FDG-PET/CT uptake, 
disease stabilization, and improvements in hypertension (20). 
Since mutations in the SDHB gene are inherited in an auto-
somal dominant manner, genetic testing and counseling are 
an integral part of multi-disciplinary care. Following surgical 
resection, the patient met with a genetic counselor to begin 
this process. The patient was born to a mother and father of 
Lebanese descent without consanguinity. Family history was 
significant for prostate cancer in father and paternal uncle 
in their 50s, and breast cancer in maternal aunt in her 40s. 
Notably, the patient did report a half-brother on his father’s 
side who had surgical resection of an abdominal mass, but 
pathology was unknown and the brother is no longer in con-
tact with the family. The patient was informed that all his 
first-degree relatives should be screened and undergo surveil-
lance if  they test positive for the mutation (21). To date, no 
family members have undergone genetic testing despite being 
encouraged to do so. 
Following the initial PET scan showing multiple sub-cen-
timeter bone metastasis, the patient received two repeat PET 
scans 2 months apart, both revealing stable disease. Treat-
ment is not being considered at this time as the patient’s 
disease course appears to be indolent, and he remains 
asymptomatic. As there are no CT correlates of the metasta-
sis, a bone biopsy would be challenging and may not be able 
to confirm the diagnosis. The patient will follow up with a 
repeat PET scan in 4 to 6 months. 
Conclusions
We present a case of a large, asymptomatic retroperitoneal 
tumor identified by abdominal imaging with ultrasound. 
Ultimately, the patient had successful surgical resection of 
the mass which was confirmed to be a PGL. Genetic test-
ing revealed a mutation in the SDHB subunit consistent with 
a diagnosis of autosomal dominant PGL4 syndrome. As a 
result, the patient is at a high risk of recurrence or the devel-
opment of other primary tumors. Additionally, the patient’s 
first-degree relatives should be screened and undergo surveil-
lance if  they test positive for the mutation. Unfortunately, 
following resection of his primary tumor 68Ga [DOTATATE] 
PET scan identified multiple small boney lesions concerning 
metastasis. What remains unknown is the oncologic potential 
of these boney deposits and an indolent course lies ahead. 
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